114,731 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Purchased by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH made a new investment in NeoGenomics, acquiring approximately $1.09 million worth of shares during the first quarter of the year.
• Several institutional investors have increased their stakes in NeoGenomics, with Allspring Global Investments boosting its holdings by 54% and GAMMA Investing increasing its stake by an impressive 1,107.7%.
• Analyst ratings for NeoGenomics have varied, with Leerink Partners downgrading the stock from "outperform" to "market perform," while Piper Sandler set a target price of $12.00 and maintained an "overweight" rating.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 114,731 shares of the medical research company's stock, valued at approximately $1,089,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of NeoGenomics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in NeoGenomics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock valued at $234,673,000 after acquiring an additional 195,793 shares in the last quarter. Greenhouse Funds LLLP raised its holdings in shares of NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after purchasing an additional 237,491 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of NeoGenomics by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock worth $56,645,000 after purchasing an additional 78,211 shares during the period. First Light Asset Management LLC grew its position in shares of NeoGenomics by 3.0% during the fourth quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock worth $52,202,000 after acquiring an additional 91,030 shares during the last quarter. Finally, Segall Bryant & Hamill LLC grew its position in shares of NeoGenomics by 11.2% during the first quarter. Segall Bryant & Hamill LLC now owns 2,350,746 shares of the medical research company's stock worth $22,309,000 after acquiring an additional 236,924 shares during the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Stock Performance

NEO stock traded down $0.12 during midday trading on Wednesday, hitting $5.51. The stock had a trading volume of 1,037,052 shares, compared to its average volume of 1,959,259. The firm has a market capitalization of $711.14 million, a price-to-earnings ratio of -6.80 and a beta of 1.54. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $19.11. The stock has a 50-day simple moving average of $6.95 and a 200 day simple moving average of $9.18. The company has a current ratio of 3.92, a quick ratio of 3.58 and a debt-to-equity ratio of 0.40.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Morgan Stanley set a $8.00 price target on shares of NeoGenomics and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Leerink Partners downgraded shares of NeoGenomics from an "outperform" rating to a "market perform" rating and cut their price target for the company from $25.00 to $9.00 in a report on Wednesday, April 30th. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Leerink Partnrs downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Finally, Wall Street Zen raised shares of NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $12.75.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault bought 7,000 shares of the stock in a transaction dated Friday, May 9th. The stock was bought at an average cost of $8.14 per share, for a total transaction of $56,980.00. Following the completion of the purchase, the director owned 7,000 shares in the company, valued at $56,980. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Aaron Kelly bought 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The stock was acquired at an average price of $7.60 per share, with a total value of $38,000.00. Following the completion of the purchase, the director owned 5,000 shares of the company's stock, valued at $38,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 17,700 shares of company stock valued at $143,886. 2.40% of the stock is currently owned by company insiders.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.